Olaparib Lynparza alternative in India

Olaparib (brand name Lynparza) was approved for use in India as a treatment for certain types of cancer, particularly ovarian and breast cancer. However, it's important to note that new medications and alternatives can become available over time.

Olaparib is an anticancer medicine referred to as the Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor.

Olaparib Tablet has been developed as a maintenance therapy to treat adult patients with cancer in the ovaries, fallopian tube, peritoneum, pancreas, and prostate due to BRCA mutation and have completely or partially responded to platinum-based chemotherapy. Olaparib Tablet is available in doses of 100mg and 150mg and the strength varies according to the patient’s health condition.

Olaparib brands in India

If you are looking for information about Olaparib (Lynparza) in India, including alternatives or availability, I recommend checking the MrMed website for low-price substitutes.

Lynparza & Bracanat 2 brands are available in India.

Lynparza Tablet: Lynparza 150mg Tablet is a targeted anticancer drug belonging to the category of PARP inhibitors. It specifically acts against ovarian cancer due to mutation in BRCA genes.

Bracanat Tablet: Bracanat 150mg Tablet is usually indicated as maintenance therapy after a person completes a platinum-based chemotherapy regimen for ovarian cancer.

Some of the common side effects of Olaparib Tablets are.

• Nausea

• Fatigue

• Gastrointestinal upset

• Anaemia (decrease in red blood cells)

• Neutropenia (decrease in neutrophils, a type of white blood cell)

If you are looking for Olaparib (Lynparza) alternatives in India, you should speak with a healthcare professional, such as an oncologist, who can provide you with the most up-to-date information on treatment options. Cancer treatment decisions are highly personalized and are influenced by factors such as the type and stage of cancer, genetic abnormalities, and a patient's overall health.

Cancer treatments, such as targeted therapies, chemotherapy, immunotherapy, and radiation therapy, are available to healthcare professionals in India. Because new drugs and treatment options are always being discovered and approved, it is critical to collaborate closely with your healthcare team to find the best treatment plan for your individual case.

Furthermore, India's pharmaceutical sector is expanding, and generic versions of Olaparib or similar medications may be accessible at a reduced cost. Your healthcare practitioner can also advise you on these possibilities.